Aveo Oncology Inc., of Cambridge, Mass., said its pivotal TIVO-3 trial, comparing tivozanib to Nexavar (sorafenib, Bayer AG) in subjects with refractory advanced renal cell carcinoma has reached its enrollment target of 322 patients. Read More
Gigagen Inc., of South San Francisco, launched its Surge Discovery service at the BIO 2017 International Conference in San Diego. The company said the antibody discovery and engineering service can deliver fully characterized monoclonal antibodies to pharmaceutical customer within six weeks, entirely replacing hybridoma and phage display. Read More
Serimmune Inc., of Santa Barbara, Calif., raised $8 million in a financing round, led by Illumina Ventures with participation from Merck & Co. Inc., of Kenilworth, N.J., and additional undisclosed investors. Read More
HONG KONG – The collaboration between Merck & Co. Inc. and South Korean company Genexine Inc. is just a few steps away from tackling human papillomavirus (HPV)-associated cancers, with Genexine receiving the go-ahead from the South Korean Ministry of Food and Drug Safety (MFDS) for a phase Ib/II trial testing a combination vaccine. Read More
Novartis AG put its VEGF-A ligand inhibitor, brolucizumab (RTH-258), to the test in neovascular age-related macular degeneration (nAMD) against Regeneron Pharmaceuticals Inc.'s cash cow, Eylea (aflibercept), and appeared to come up a winner. Read More
SAN DIEGO – Buzzing through the halls, amid private discussions and public panels, a technology that some say could dramatically transform therapeutic development teeters at the forefront of many BIO 2017 discussions. Read More
SAN DIEGO – Glenmark Pharmaceuticals Inc. has struck a deal to license a small-molecule cancer candidate from APC Therapeutics Inc., gaining worldwide development and commercialization rights to a compound based on antigen-presenting cell (APC) biology with potential as a monotherapy or in combination with existing therapies, it said. Read More
In one of the largest private financings of the year, 3-year-old Rubius Therapeutics Inc. raised $120 million in an oversubscribed round to build out the company and advance its lead Red-Cell Therapeutics candidates into the clinic. Read More
SAN DIEGO – "I think we have a real shot," Axovant Sciences Ltd. CEO David Hung told a rapt audience, speaking about the phase III MINDSET trial in more than 1,300 patients with Alzheimer's disease (AD). Eagerly awaited results with the 5HT6 therapy RVT-101 (intepirdine) are due in September, and hopes are that the positive phase II data from a 684-patient experiment will be duplicated. Read More
